MSME (Udyam registered) Ministry of MSME
- Category
- Micro (2024-25)
- Udyam number
- UDYAM-TN-02-0063993
Medcorpus Pharmaceuticals Private Limited
Medcorpus Pharmaceuticals Private Limited - pharma in Kolathur, Tamil Nadu, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹69.28 Lakh
▲ 4% YoY
Net profit · FY 2025
₹1.11 Lakh
Net margin 1.6%
EBITDA · FY 2025
₹4.64 Lakh
EBITDA margin 6.7%
Authorised capital
₹10 Lakh
Registered with MCA
Paid-up capital
₹1.5 Lakh
Issued & subscribed
Company age
10 yrs
Est. 2016
Directors on board
3
As per MCA filings
Active GSTINs
1
GST registered
About Medcorpus Pharmaceuticals Private Limited
Data last updated:
Medcorpus Pharmaceuticals Private Limited is a private limited company based in Kolathur, Tamil Nadu, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 19 September 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN U51909TN2016PTC112571. Its GSTIN is 33AAKCM5955F1ZB (Tamil Nadu).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1.5 Lakh. It is led by directors including Pragadeeswaran and Thangaraj Subbiah.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at No.1 (10) Ground Floor Jayaram Nagar 1st Main Road Jayaram Nagar, Kolathur, Tamil Nadu, India – 600099.
As per the financials filed for FY 2025, the company reported a revenue of ₹69.28 Lakh, a growth of 4% compared to the previous year. For the same year it recorded a net profit of ₹1.11 Lakh (net margin 1.6%) and EBITDA of ₹4.64 Lakh (EBITDA margin 6.7%). Revenue has declined at a compounded annual rate (CAGR) of 6% over three years.
Medcorpus Pharmaceuticals Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-TN-02-0063993). The current compliance status is marked as compliant by the Registrar of Companies.
Company details
CIN U51909TN2016PTC112571
Registration Number 112571
Incorporation Date 19 September 2016
ROC Chennai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Micro
Udyam Registration UDYAM-TN-02-0063993
Recognitions & Rankings of Medcorpus Pharmaceuticals
Contact details
Medcorpus Pharmaceuticals Private Limited's registered office is in Kolathur, Tamil Nadu. Its e-mail address is in the company report.
- Email
- Registered AddressNo.1 (10) Ground Floor Jayaram Nagar 1st Main Road Jayaram Nagar, Kolathur, Tamil Nadu, India – 600099
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Medcorpus Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Medcorpus Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Medcorpus Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Medcorpus Pharmaceuticals Private Limited, buy the company report.
Financials of Medcorpus Pharmaceuticals Private Limited
FY 2025 filings availableMedcorpus Pharmaceuticals Private Limited reported revenue of ₹69.28 Lakh (up 4% YoY) for FY 2025.
Revenue · FY 2025
₹69.28 Lakh ▲ 4%
Net profit · FY 2025
₹1.11 Lakh margin 1.6%
EBITDA · FY 2025
₹4.64 Lakh margin 6.7%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 4%
3 years · compounded
▼ 6%
EBITDA CAGR growth
1 year
▼ 10%
3 years · compounded
▲ 8%
5 years · compounded
▲ 26%
Revenue rose 4% in the latest year, though over three years it has declined at a compounded annual rate (CAGR) of 6%. EBITDA fell 10% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹4.64 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.11 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 6.7% | ||||
| Net Profit Margin | 1.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Medcorpus Pharmaceuticals Private Limited, buy the company report.
Board of directors of Medcorpus Pharmaceuticals Private Limited
Medcorpus Pharmaceuticals has 3 directors on record. No former directors are listed.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pragadeeswaran | Director | 19 Sep 2016 | 10 Years 1 Months | Current |
| Thangaraj Subbiah | Director | 19 Sep 2016 | 10 Years 1 Months | Current |
| Kannan Gurumurthy | Director | 19 Sep 2016 | 10 Years 1 Months | Current |
Peer comparison
Medcorpus Pharmaceuticals Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Deemar Pharmaceuticals Private Limited | ₹69.5 Lakh (FY 2025) | 46233.0% | Hyderabad, Telangana, India | |||
| Neutron Medicals Private Limited | ₹69.44 Lakh (FY 2020) | 64.0% | Pune, Maharashtra, India | |||
| Auriga Life Sciences Private Limited | ₹69.33 Lakh (FY 2019) | -2.0% | Kochi, Kerala, India | |||
| Medcorpus Pharmaceuticals Private Limitedthis company | ₹69.28 Lakh (FY 2025) | ₹1.11 Lakh | 1.6% | 4.0% | Kolathur, Tamil Nadu, India | |
| Caprice Healthcare Private Limited | ₹69.19 Lakh (FY 2025) | -15.0% | Ernakulam, Kerala, India |
To see the full peer comparison of Medcorpus Pharmaceuticals Private Limited, buy the company report.
Auditor
Medcorpus Pharmaceuticals Private Limited is audited by MOULI & REDDY ASSOCIATES for the financial year 2018.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| MOULI & REDDY ASSOCIATES | FY 2018 | 002138S |
Shareholding
The shareholding of Medcorpus Pharmaceuticals Private Limited is on record for FY 2018, split between promoters, domestic institutions, public shareholders and others.
| Shareholder category | FY 2018 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Public | |
| Others |
To see the full shareholding pattern of Medcorpus Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Medcorpus Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Medcorpus Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Medcorpus Pharmaceuticals has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 33AAKCM5955F1ZB | Tamil Nadu | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Medcorpus Pharmaceuticals Private Limited, buy the company report.
Recent activity
Medcorpus Pharmaceuticals Private Limited has 3 board changes on record since 2016: 3 appointments. The latest: Kannan Gurumurthy was appointed as Director on 19 Sep 2016.
AGM
Medcorpus Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Medcorpus Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Chennai.
Appointed
Kannan Gurumurthy was appointed as Director.
Appointed
Pragadeeswaran was appointed as Director.
Appointed
Thangaraj Subbiah was appointed as Director.
Incorporation
19 Sep 2016
Medcorpus Pharmaceuticals Private Limited was registered on 19 Sep 2016 with Roc Chennai & aged 10 years 1 month as per MCA records.
Frequently asked questions
Medcorpus Pharmaceuticals is an active private limited company based in Kolathur, Tamil Nadu, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 19 September 2016 (10+ years old) and is registered under CIN U51909TN2016PTC112571.
Medcorpus Pharmaceuticals has 3 current directors:
- Pragadeeswaran - Director
- Thangaraj Subbiah - Director
- Kannan Gurumurthy - Director
The latest financial statements of Medcorpus Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Medcorpus Pharmaceuticals is 33AAKCM5955F1ZB, registered in Tamil Nadu.
The CIN (Corporate Identification Number) of Medcorpus Pharmaceuticals is U51909TN2016PTC112571. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Medcorpus Pharmaceuticals was incorporated on 19 September 2016, making it 10+ years old. It is registered with the Registrar of Companies, Chennai.
The peers of Medcorpus Pharmaceuticals by revenue are Deemar Pharmaceuticals Private Limited, Neutron Medicals Private Limited, Auriga Life Sciences Private Limited, Caprice Healthcare Private Limited, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Kannan Gurumurthy was appointed as Director on 19 Sep 2016. Pragadeeswaran was appointed as Director on 19 Sep 2016. Thangaraj Subbiah was appointed as Director on 19 Sep 2016.
Yes, Medcorpus Pharmaceuticals is registered as a micro enterprise under Udyam registration (number: UDYAM-TN-02-0063993).
The registered office of Medcorpus Pharmaceuticals is at No.1 10 Ground Floor Jayaram Nagar 1st Main Road Jayaram Nagar, Kolathur, Tamil Nadu, India – 600099.
Medcorpus Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.